ALN-F12

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameALN-F12
Drug Alias NameGalNac-conjugated siRNA (Alnylam Pharmaceuticals)siRNA-targeting F12 gene expression (Alnylam Pharmaceuticals)ALN-F12
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionCoagulation factor XII expression inhibitors
TargetsCoagulation factor XII
Therapy Area/IndicationsThrombosisAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsThrombosisAngioedemas, Hereditary

Other Information

ATC CodeN/A
Related LinksN/A